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Angiogenesis, the process by which new blood
vessels arise from preexisting ones, is critical for
embryonic development and is an integral part of
many disease processes. Recent studies have
provided detailed information on how angiogenic
sprouts initiate, elongate, and branch, but less is
known about how these processes cease. Here, we
show that S1PR1, a receptor for the blood-borne
bioactive lipid sphingosine-1-phosphate (S1P), is
critical for inhibition of angiogenesis and acquisition
of vascular stability. Loss of S1PR1 leads to
increased endothelial cell sprouting and the forma-
tion of ectopic vessel branches. Conversely, S1PR1
signaling inhibits angiogenic sprouting and enhances
cell-to-cell adhesion. This correlates with inhibition
of vascular endothelial growth factor-A (VEGF-A)-
induced signaling and stabilization of vascular endo-
thelial (VE)-cadherin localization at endothelial junc-
tions. Our data suggest that S1PR1 signaling acts
as a vascular-intrinsic stabilization mechanism, pro-
tecting developing blood vessels against aberrant
angiogenic responses.
INTRODUCTION
During development, the cardiovascular system faces the
complex challenge of remaining functional, while simultaneously
adapting to the growing body’s increasing need for oxygen andDevelopmennutrients. Following de novo assembly from mesoderm-derived
endothelial precursors (vasculogenesis), a primitive vascular
network progressively develops hierarchical organization and
functional specialization through a process termed angiogen-
esis, which involves sprouting, splitting, growth, and remodeling
of vessels. Sprouting initiates by the formation of migratory
endothelial cells (tip cells), a process driven by vascular endothe-
lial growth factor (VEGF) (Gerhardt et al., 2003). A single tip cell
occupies the lead position of the sprout, whereas trailing endo-
thelial cells (stalk cells) shape the lumenized shaft. The segrega-
tion of the sprouting endothelial cells into tip cells and stalk
cells is regulated by Notch (reviewed in Eilken and Adams,
2010 and Phng andGerhardt, 2009). However, unlikemany other
Notch-dependent cell differentiation phenomena, which lock
cell differentiation to a specific fate, the tip and stalk cell
phenotypes appear dynamic and reversible, as endothelial cells
rapidly shuffle at the lead position (Jakobsson et al., 2010).
Besides tissue VEGF-A gradients, (Gerhardt et al., 2003;
Ruhrberg et al., 2002), the direction of sprout protrusion depends
on a number of other ligands and receptors that regulate tip
cell guidance mainly by repulsion, including members of the
Ephrin/EPH, Slit/ROBO, Netrin/UNC5B, and Semaphorin/Plexin
families (reviewed in Adams and Eichmann, 2010 andWeinstein,
2005).
As embryonic development proceeds, there is an increasing
need for vascular stabilization. Whereas angiogenic sprouting
and endothelial cell proliferation continue in the distal parts of
the growing vascular tree, branch patterns, identities, and hierar-
chies simultaneously need to be stabilized at proximal locations.
The term vascular stability, although commonly used in review
literature, is largely descriptive, as the molecular mechanisms
involved are poorly understood.tal Cell 23, 587–599, September 11, 2012 ª2012 Elsevier Inc. 587
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S1P/S1PR1 Restricts Angiogenic SproutingBlood flow has been implicated as a vessel-stabilizing mech-
anism through the oxygenation of tissues, leading to downregu-
lation of hypoxia-sensitive pro-angiogenic factors, like VEGF-A.
Blood flow also delivers S1P, which occurs in micromolar
concentrations in plasma, whereas tissue concentrations of
S1P are usually in the nanomolar range (Hla et al., 2008). The
vast majority of circulating plasma S1P is produced from eryth-
rocytes and endothelial cells through the activity of sphingosine
kinases (SPHKs) (Pappu et al., 2007; Venkataraman et al., 2008).
S1P binds to and activates a family of five G protein–coupled
receptors in mammals, S1P receptor 1 to 5 (S1PR1-5), formerly
known as endothelial differentiation gene (EDG)-receptors (Hla
et al., 1999). Of these, S1PR1, S1PR2, and S1PR3 have been
reported to be expressed in endothelial cells (Kono et al., 2004).
S1P receptor signaling has been implicated atmultiple steps in
cardiovascular physiology, including regulation of vascular
permeability, mural cell recruitment, lymphocyte trafficking,
inflammation, coagulation, and cardiac function (reviewed in
Hla et al., 2008 and Rivera et al., 2008). Complete S1P depletion
through genetic ablation of bothSphk1 andSphk2 inmice results
in neurological and vascular defects (Mizugishi et al., 2005).
These embryos die between embryonic days (E) 11.5–13.5, dis-
playing severe hemorrhage. Their vascular defects are charac-
terized by dilated vessels and reduced vascular smooth muscle
cell (vSMC) coverage of the dorsal aorta. A similar phenotype
was observed when S1PR1, S1PR2, and S1PR3 were depleted
in combination. Single, double, or triple knockout combinations
of these receptors demonstrate that S1PR1 and S1PR3 function,
in part, redundantly during vascular development, but that
S1PR1 is the most important receptor (Kono et al., 2004). In
S1pr1 single knockout mice, embryonic lethality occurs slightly
later than in the triple knockouts (E12.5–14.5) (Liu et al., 2000).
The lethality of these mice has been attributed to incomplete
vascular maturation, due to deficient coverage of vascular mural
cells (vascular smooth muscle cells [vSMC] and pericytes).
However, early vasculogenesis and angiogenesis were reported
to proceed normally (Allende et al., 2003; Liu et al., 2000; Paik
et al., 2004). Other studies have implicated S1P in angiogenesis
through in vitro analysis, suggesting a pro-angiogenic role
(Bayless and Davis, 2003; Paik et al., 2001).
Our previous studies of pericyte-deficient platelet derived
growth factor (PDGF)-B and PDGF receptor beta (PDGFRb)
null mice demonstrate the critical importance of murals cells
for vascular development and embryonic survival. However,
this occurs at a significantly later step, and is associated with
milder vascular abnormalities compared to the S1pr1/ mice
(Hellstro¨m et al., 1999; Leve´en et al., 1994; Lindahl et al., 1997;
Soriano, 1994). This prompted us to further analyze the role of
S1P/S1PR1 signaling in vascular development. Here, we report
that this signaling pathway inhibits angiogenic sprouting and
promotes vascular stability in the endothelium in a cell autono-
mous manner. Based on genetic experiments in mouse and
zebrafish, as well as on the use of an S1PR1-specific agonist
and antagonist in vivo, ex vivo, and in vitro, we propose that
S1P provides essential protection of the developing vasculature
against unrestrained angiogenic sprouting and ectopic vessel
branch formation. These functions are mediated by endothelial
S1PR1, which in turn regulates the interplay between VE-
cadherin and VEGFR2.588 Developmental Cell 23, 587–599, September 11, 2012 ª2012 ElsRESULTS
Loss of S1PR1 in Mice Leads to Angiogenic
Hypersprouting, whereas Mural Cell Recruitment
and Coverage Are Normal
To investigate whether the reported pericyte deficiency in
S1pr1/ mice was a result of problems with initial recruitment
or subsequent survival/maintenance of the mural cell coat, we
analyzed the embryonic hindbrain, an organ well suited to the
study of pericyte recruitment in conjunction with embryonic
angiogenesis at midgestation (Abramsson et al., 2007; Gerhardt
et al., 2004). Much to our surprise, we observed that pericyte
recruitment and mural cell coverage of the hindbrain vasculature
was normal in S1pr1/ embryos (Figure 1A; Figure S1A avail-
able online). However, we instead noted endothelial hyper-
sprouting from E11.5 onward, as reflected by increased
numbers of endothelial tip cells, increased protrusions of endo-
thelial filopodia, and increased overall vascular density. This
phenotype was seen in hindbrains (Figures 1B and S1B; data
not shown), as well as in other locations, including the neural
tube and the developing limbs (Figure S1C). We also studied
the effects of S1pr1 deletion on postnatal retinal angiogenesis.
In the retina, S1PR1 expression is restricted to the vascular
endothelium, as shown by S1pr1-lacZ reporter analysis (Fig-
ure 1Ci), but it differed in intensity, being strongest in arterial
branches (Figure 1Cvii–1Cix), followed by veins (Figure 1Cx)
and capillaries (Figure 1Cv). Cells at the sprouting front, including
tip cells, showed the lowest expression of S1pr1-lacZ (Fig-
ure 1Ci–1Civ). We induced S1pr1 gene deletion specifically in
endothelial cells using VE-cadherin (Cdh5) promoter-driven Cre
recombinase expression by administrating tamoxifen into
newborn Cdh5(PAC)-CreERT2 (Pitulescu et al., 2010); S1pr1fl/fl
(Allende et al., 2003); R26R-EYFP mice (Srinivas et al., 2001)
(hereafter referred to as iEC-S1pr1KO). Although tamoxifen-
induced recombination in the retinal endothelium was always
mosaic, as revealed by the R26R-YFP reporter, endothelial
hypersprouting and increased endothelial cell density was
clearly evident and was invariably associated with abundant
pericyte coverage (Figure 1D; see also Figure 4A for additional
illustration of hypersprouting). YFP+ cells, with increased likeli-
hood of also being S1pr1 null, occupied almost all tip cell posi-
tions in these retinas, in marked contrast to overall chimerism
(Figure 1E). This suggests that the effect of S1PR1 is cell
autonomous, and that loss of S1PR1 causes endothelial cells
to acquire a tip cell phenotype. In addition to the retinal micro-
vasculature, retained mural cell coverage was also observed in
retinal arteries and veins that had undergone Cre-mediated
recombination (Figure S1D).
In summary, these results demonstrate angiogenic hyper-
sprouting with retained pericyte coverage in S1pr1-deficient
mice. Our analysis also shows that the endothelial hypersprout-
ing phenotype results from loss of S1PR1 signaling in endothelial
cells.
Aortic Hyperbranching in S1pr1-Deficient Mice Causes
Progressive Vascular Derangement
The most striking reported loss of mural cells in S1pr1/ and
Sphk1/2 double knockouts occurred around the developing
aorta (Liu et al., 2000; Mizugishi et al., 2005; Paik et al., 2004).evier Inc.
Figure 1. Genetic Ablation of S1pr1 in Mice Leads to Angiogenic Hypersprouting with Retained Mural Cell Coverage
(A and B) Vascular patterns in the E11.5mouse hindbrain. Ventricular views of the developing subventricular zone vascular plexus. Endothelial cells are stained by
isolectin B4 (IB4) and pericytes by NG2. Arrowheads in (A) point at pericytes, in (B) at ectopic filopodia.
(C) Analysis of S1pr1 expression in the developing (P5) retina shows expression in endothelial cells but not in vSMC. S1pr1-lacZ staining (blue/black intracellular
aggregates) combined with staining for endothelial cells and vSMC, as indicated. The top row of images (i–v) display a retinal whole mount (i, arrowhead pointing
at strong lacZ staining in a central large vessel, whereas the lacZ expression at the periphery (asterisk) is weaker) followed by high magnification images of the
sprouting front (ii–v). In the high magnification image (v), arrowheads point to lacZ aggregates in the retinal microvasculature. The bottom row of images (vi–x)
displays endothelial cell/vSMC staining of arteries and veins at central locations in the retina. Arrowheads in (ix) point at S1pr1-lacZ negative arterial vSMC.
(D) Vascular patterns in the postnatal retina of iEC-S1pr1KO mice. YFP expression indicates tamoxifen-induced recombination at the R26R-EYFP locus.
(E) Sprouting front of retinal vascular plexus in iEC-S1pr1KO. Note that YFP+ cells preferentially occupy the tip cell position in a background of mostly un-
recombined cells.
See also Figure S1.
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Figure 2. Ectopic Branching and Glomeru-
loid Vascular Malformations around the
Aorta in S1pr1 Knockouts
(A) Vascular phenotypes in and around the devel-
oping aorta in embryos at E11.5–13.5. Ectopic
connections between glomeruloid regions (aster-
isks) and the aorta are indicated by arrowheads.
Position of notochord (n) and aorta (ao) are indi-
cated in relevant sections.
(B) Phenotypic appearance of the aorta in
S1pr1/ embryos at different levels along the
anterior-posterior axis. Approximate section plane
is illustrated (X0 or Y0).
(C) Quantifications of aortic branch points per
cross section in three E12.5 wild-type and three
S1pr1/ embryos.
(D) A similar but milder aortic phenotype is
observed in iEC-S1pr1KO embryos. Sections are
stained for IB4 (endothelium) NG2 (pericytes),
aSMA (vSMC), and Dapi (nuclei). All values are
mean ± SD.
See also Figure S2.
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S1P/S1PR1 Restricts Angiogenic SproutingWe confirmed that the aortic vSMC coverage was abnormal in
S1pr1/ embryos (Figures 2A and S2A), but this defect was
accompanied by a massive endothelial hyperplasia and
abnormal microvasculature around the aorta. This vasculature
formed glomeruloid lesions with numerous ectopic endothe-
lium-lined connections to the aortic lumen (Figures 2A–2C,
S2A, and S2D). At E11.5, the lesions were mainly concentrated
on the dorsal side of the aorta, whereas at E12.5 they often
occurred in lateral regions as well. By E13.5, the lesions
frequently surrounded the aortic circumference (Figure 2A).
Also, the major branches of the aorta, such as the femoral, tail,
and intercostal arteries were associated with glomeruloid lesions590 Developmental Cell 23, 587–599, September 11, 2012 ª2012 Elsevier Inc.(Figures S1C and S2A; data not shown).
The lesions contained abundant mural
cells and basement membrane proteins
(Figures 2A, S2A, and S2D). At E13.5,
but not earlier, we observed massive
induction of apoptosis in endothelial cells,
as well as in neighboring dorsal root
ganglia (Figure S2B; data not shown),
a phenotype that likely contributes to the
rapid demise and synchronous death
of the embryos between E13.5 and
E14. Using the S1pr1-lacZ reporter, we
confirmed that the aortic endothelium,
but not the surrounding vSMC or other
adjacent tissues, is a major site of S1pr1
expression in mouse embryos (Fig-
ure S2C). That the endothelial lesions
are likely endothelial cell autonomous
was supported by analysis of iEC-
S1pr1KO embryos obtained through
tamoxifen administration into pregnant
females. These embryos displayed an
aortic phenotype that was qualitatively
similar but milder than in S1pr1/
embryos (Figure 2D). The milder pheno-type is likely explained by endothelial mosaicism for S1pr1 dele-
tion and/or by a delay in the elimination of S1PR1 protein
following genetic recombination of the S1pr1 locus.
To our knowledge, aortic hyperbranching has not been re-
ported in other vascular mutants, and we therefore considered
it specific, or even pathognomonic, for disrupted S1PR1 signal-
ing. To address the possibility that the observed aortic pheno-
type may nevertheless constitute a systemic and previously
overlooked consequence of vascular dysfunction associated
with embryonic lethality around E14, we studied Ramp2/
embryos, which die around E14.5 as a result of vascular abnor-
malities (Fritz-Six et al., 2008; Ichikawa-Shindo et al., 2008).
Figure 3. Effects of S1PR1-Specific Antago-
nist and Agonist In Vivo, Ex Vivo, and In Vitro
(A) Angiogenic hypersprouting in the newborn
mouse retina, as indicated by increased numbers
of tip cells and filopodia, following systemic
administration of the S1PR1 antagonist (R)-W146.
(B andC) Treatment of aortic ring explants with (R)-
W146 or SEW2871 has opposite effects on sprout
morphology and numbers of developing branches.
(B) VE-cadherin fluorescent staining of fixed aortic
rings. (C) Phase contrast microscopy and statis-
tical analysis of live aortic ring cultures at low
magnification (left), high magnification fields dis-
playing sprouts (middle, black arrowheads) and
detached cells (black arrow), and examples of how
branch numbers were counted (right; red dot
indicates branch point).
(D) MS-1 cell-covered beads allowed to sprout in
fibrin gels. Sprouts and scattered cells were
scored in phase contrast microscopy. The top
panel shows images of beads and cells, and indi-
vidual sprouts connected to the bead (red dots)
and scattered cell (blue dots). Right panel shows
the quantified results and statistics. Note that the
VEGF-induced cell detachment and scattering is
enhanced by the S1PR1 antagonist (R)-W146 and
inhibited by the agonists S1P and SEW2871. All
sprouting effects are efficiently inhibited by the
VEGFR2 tyrosine kinase inhibitor SU4516. Statis-
tically significant differences are indicated. All
values are mean ± SD. The p value is indicated
(* = p < 0.05); Student’s t test.
See also Figure S3.
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S1P/S1PR1 Restricts Angiogenic SproutingRamp2/ mutants did not show signs of aortic hyperbranching
(Figure S2E). We also failed to observe aortic hyperbranching in
Dll4+/ embryos and embryos with induced endothelial-specific
deletion of the Notch-target RBP-J (tamoxifen-treated
Cdh5(PAC)-CreERT2; Rbp-jfl/fl) (Figure S2E), yet both of these
mutants displayed the expected angiogenic hypersprouting at
other locations (data not shown). These data also provide
evidence against the initial suspicion that S1PR1 signaling
impinges upon the Notch pathway, a conclusion further corrob-
orated by microarray (data not shown) and Q-PCR analysis of
microvascular fragments (Figure S2F), which failed to show
any consistent and significant changes in the expression of
Notch target genes in S1pr1/ embryos. These analyses
instead revealed that the VE-cadherin target gene growth arrest
specific-1 (Gas1) (Spagnuolo et al., 2004), as well as the S1P
receptors S1pr1 and S1pr3, were significantly downregulatedDevelopmental Cell 23, 587–599, Sein S1pr1/ embryonic vasculature (Fig-
ure S2F), suggesting crosstalk with other
S1P receptors and with VE-cadherin.
Antagonists and Agonists of
S1PR1 Have Opposing Effects
on Angiogenic Sprouting and
Endothelial Cell-Cell Adhesion
To obtain insight into the morphogenetic
basis for the observed angiogenic
phenotypes in S1pr1 mutants, we testedselective S1PR1 antagonists and agonists for their effects on
angiogenic sprouting in vivo, ex vivo, and in vitro. In agreement
with the gene knockout data, systemic administration of the
S1PR1-specific antagonist (R)-W146 (Sanna et al., 2006) to
newborn mice resulted in endothelial hypersprouting in the
postnatal retina (Figure 3A). Similar results were obtained when
(R)-W146 was added ex vivo to mouse aortic ring cultures.
Here, (R)-W146 led to increased density of endothelial sprouts,
whereas treatment with the S1PR1-specific agonist SEW2871
led to the formation of fewer, longer, and less branched sprouts
(Figures 3B and 3C).
We next studied in vitro assays for sprouting angiogenesis,
in which human umbilical vein endothelial cells (HUVECs) or
mouse MS-1 microvascular endothelial cells seeded on beads
were allowed to sprout in fibrin gels in the presence or absence
of exogenously added VEGF. In both the HUVEC and MS-1ptember 11, 2012 ª2012 Elsevier Inc. 591
Figure 4. Induced Endothelial-Specific
Knockouts ofS1pr1 andCdh5 inMice Cause
Similar Angiogenic Hypersprouting in the
Postnatal Retina
Analysis of vasculature in whole-mounted retinas.
(A) P8 retinas from control, iEC-Cdh5KO and
iEC-S1pr1KO mice shows that endothelial-
specific VE-cadherin deletion, similar to S1pr1
deletion, leads to the formation of a dense vessel
network (white asterisk), delayed plexus extension
at the margins, and loss of hierarchical vessel
organization. Analysis at higher magnification
reveals angiogenic hypersprouting at the vascular
front in the iEC-Cdh5KO retina similar to the
iEC-S1pr1KO situation, as indicated by increased
numbers of tip cells and endothelial filopodia.
(B) Loss of VE-cadherin protein in iEC-Cdh5KO
retinas was verified by immunohistochemistry
against VE-cadherin. Note near complete loss of
VE-cadherin staining in the iEC-Cdh5KO retina
(yellow asterisk) and the occasional residual
expression of immuno-reactive VE-cadherin with
abnormal cellular localization (yellow arrowheads).
Collagen IV deposits were less confined to the
endothelial cells at the sprouting front of iEC-
Cdh5KO retinas, indicating increased cell migra-
tion. All values are mean ± SD. The p value is
indicated; Student’s t test.
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S1P/S1PR1 Restricts Angiogenic Sproutingassays, VEGF promoted the formation of sprouts led by tip
cells, an effect that was efficiently blocked by SEW2871
(Figures 3D and S3A). Conversely, (R)-W146 enhanced the
VEGF-dependent formation of sprouts and, moreover, caused
a large increase in the number of scattered cells (Figures 3D
and S3A). The sequential addition of SEW2871 and (R)-W146
to bead cultures recorded by time lapse microscopy demon-
strated that (R)-W146 strongly promoted endothelial cell scat-
tering, which was reversible following readdition of SEW2871,
leading to coalescence of the scattered endothelial cells into
vessel-like aggregates (Movie S1). The effects of (R)-W146
were neutralized by SU5416, a potent and selective inhibitor
of VEGFR2 (Fong et al., 1999), suggesting that VEGF signaling
is necessary for the angiogenic effects of S1PR1 inhibition
(Figure 3D).
In summary, experiments using S1PR1-specific pharmaco-
logical ligands show that S1PR1 inhibition promotes VEGF-592 Developmental Cell 23, 587–599, September 11, 2012 ª2012 Elsevier Inc.induced sprouting in vivo, ex vivo, and
in vitro, in agreement with the mouse
knockout data. In contrast, S1PR1 activa-
tion promotes endothelial cells aggrega-
tion and assembly into cords, and inhibits
VEGF-induced cellular responses.
VE-Cadherin Knockout
In Vivo Leads to Angiogenic
Hypersprouting and Reduced
Endothelial Cell-Cell Adhesion
The endothelial cell scattering following
S1PR1-inhibition in combination with
VEGF stimulation raised the possibilitythat S1PR1 regulates angiogenic sprouting by effecting endo-
thelial cell-cell adhesion. In fact, VE-cadherin, a major endothe-
lial adherens junction protein, has previously been implicated as
a target for S1P signaling in cultured endothelial cells (Lee et al.,
1999). A role of VE-cadherin in mediating S1PR1-induced
inhibition of angiogenic sprouting would infer that ablation, or
knockdown, of VE-cadherin in vivo should phenocopy, partially
or fully, the pro-angiogenic effects of ablation or knockdown
of S1PR1. We tested this by inducing VE-cadherin deletion in
endothelial cells through administration of tamoxifen into
newborn Cdh5(PAC)-CreERT2; Cdh5fl/fl mice (hereafter referred
to as iEC-Cdh5KO). To facilitate the analysis of angiogenic
sprouting and comparison with the iEC-S1pr1KO mice, we
focused our analysis to the postnatal retina. As shown in Figures
4A and 4B, iEC-Cdh5KO led to prominent retinal angiogenic
hypersprouting, as reflected by increased numbers of tip cells
and filopodia and an overall increase in the vascular density.
Figure 5. S1PR1 Signaling Regulates VE-
Cadherin Localization at Endothelial Cell
Junctions
(A) Mislocalization of VE-cadherin at endothelial
junctions in developing P7 iEC-S1pr1KO retinas.
Whereas VE-cadherin staining is distinctly junc-
tional in controls, the staining is diffuse (yellow
asterisks), irregular and often decreased in iEC-
S1pr1 KO (yellow arrows; compare to control
vessels indicated by yellow arrowheads).
(B) siRNA-mediated knockdown of S1PR1 in MS-1
cells leads to loss of VE-cadherin and VEGFR2
from junctions, an effect that is strengthened by
VEGF. A scrambled siRNA (Scr) lacked effect.
(C) Effects of S1PR1 ligands and VEGF on VE-
cadherin and VEGFR2 junctional localization in
MS-1 cells. Note the dose-dependent down-
regulation of junctional VE-cadherin induced by
VEGF, and its efficient reversal by S1PR1 agonists,
whereas the antagonist (R)-W146 has the opposite
effect and potentiates VE-cadherin and VEGFR2
loss from junctions and intracellular pools.
(D) Time course of VEGF-induced VE-cadherin
downregulation in MS-1 cells. Note the effect of
extracellular VEGF trapping by sFlt1, indicating
that cultured MS-1 cells produce autocrine VEGF.
The endocytosis inhibitor Dynasore (Dyna) has
a similar effect as S1P, leading to an accumulation
of VE-cadherin at junctions.
(E) In MS-1 cells, the protection of VE-cadherin
from extracellular trypsin digestion, i.e., its inter-
nalization, is increased by VEGF, an effect effi-
ciently blocked by S1P.
See also Figure S4.
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S1P/S1PR1 Restricts Angiogenic SproutingThese phenotypes were qualitatively similar in iEC-Cdh5KO
and iEC-S1pr1KO mice, but strongest in the iEC-Cdh5KO mice
(Figure 4A). Loss of VE-cadherin protein in iEC-Cdh5KO
retinas was confirmed by immunohistochemistry (Figure 4B).
We also observed detaching tip cells that had poor cellular
connections to the vascular plexus at the angiogenic front in
iEC-Cdh5KO retinas (Figure 4B), and, to a lesser extent, in iEC-
S1pr1KO retinas (data not shown), but never in controls. In
iEC-Cdh5KO retinas, the endothelial cells, including detaching
tip cells, showed signs of increased motility in mutants, as indi-
cated by widespread collagen IV staining (Figure 4B), which
provides a record of endothelial cell movements in the tissue
(Inai et al., 2004).Developmental Cell 23, 587–599, SeS1PR1 Signaling Regulates
VE-Cadherin Localization at
Endothelial Cell Junctions
If the angiogenic hypersprouting ob-
served in the S1PR1-deficient situations
was mediated by reduced junctional VE-
cadherin, one would expect VE-cadherin
mislocalization to occur as a result of
S1PR1 inhibition. Indeed, we observed
abnormal VE-cadherin localization in the
retina of iEC-S1pr1KO mice (Figure 5A).
In controls, VE-cadherin decorated endo-
thelial junctions in regular patterns, yetthe S1pr1KO retinas displayed irregular VE-cadherin staining,
which was heterogeneous in intensity and less distinctly junc-
tional. The observed effects on VE-cadherin mislocalization
became evident from P7, whereas they were less clear at earlier
stages (data not shown), likely related to slow turnover of the
VE-cadherin protein. Notably, whereas tip cells in control retinas
were invariably VE-cadherin positive, many tip cells in P7
S1pr1KO retinas displayed low, irregular, or even undetectable
VE-cadherin staining (Figure 5A). The cell-autonomous nature
of this phenotype was evident in low-degree chimeras, in which
recombined single cells or cell clones were associated with
abnormal VE-cadherin staining in an otherwise normal vascular
background (Figure S4A).ptember 11, 2012 ª2012 Elsevier Inc. 593
Figure 6. S1PR1 and VE-Cadherin Cooperate to Inhibit Angiogenic Sprouting and Promote Vascular Stabilization
(A) Analysis of zebrafish morphants. s1pr1 and cdh5 morphants display pericardial and hindbrain edema (black arrowheads). High-resolution analysis of the
developing hindbrain is focused on developing central arteries (CtAs; white). The lateral primordial hindbrain channels (PHBC) and midline basilar artery (BA) are
shown for reference (green in overview panel). Normally, developing CtAs display well-demarcated tip cells and associated filopodia (yellow arrows), whereas
s1pr1 or cdh5 knockdown leads to hypersprouting (yellow asterisks), including increased numbers of tip cells and filopodia. Middle and bottom panels show
hindbrain vasculature in sphk1, silent heart (tnnt2), and s1pr1 and cdh5 morphants, as indicated. Note that single low dose s1pr1 and cdh5 morpholinos lack
Developmental Cell
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Developmental Cell
S1P/S1PR1 Restricts Angiogenic SproutingThe in vivo effects of S1PR1 depletion on VE-cadherin levels
were reproduced in vitro. SiRNA-mediated knockdown of
S1pr1 resulted in loss of VE-cadherin from junctions (Figures
5B and S4B). Conversely, and in agreement with previous results
(Lee et al., 1999), S1P stimulation led to increased junctional
VE-cadherin staining (Figure 5C). VEGF stimulation, on the
contrary, triggered a rapid decrease in junctional VE-cadherin,
recapitulating previously reported observations (Gavard and
Gutkind, 2006) (Figures 5C, 5D, and S4C). Strikingly, we found
that VEGF-mediated reduction of junctional VE-cadherin was
completely blocked by S1P or SEW2871 (Figures 5C and 7B),
suggesting a functional antagonism of S1P and VEGF signaling
on the level of VE-cadherin at cell junctions.
The S1P-induced increase in junctional VE-cadherin was also
observed when VEGFR2 signaling was inhibited either in the
presence of sFlt1 (Figure S4D) or through SU5416 (Figure S4E),
suggesting that S1P has direct effects on VE-cadherin localiza-
tion, independent of the inhibition of VEGF-induced responses,
including the ones elicited by endogenous autocrine VEGF. As
expected, the S1PR1 antagonist (R)-W146 had the opposite
effect compared to S1P or SEW2871, potentiating the VEGF-
induced internalization of VE-cadherin (Figure 5C). In agreement
with the immunofluorescence data, VEGF stimulation caused an
increase in the trypsin-insensitive (i.e., internalized) pool of VE-
cadherin, an effect efficiently blocked by S1P (Figure 5E).
Together, these data show that S1PR1 signaling positively and
directly regulates the level of VE-cadherin at endothelial junc-
tions, an effect that overrides the negative effect of VEGF on
junctional VE-cadherin concentrations.
S1PR1 and VE-Cadherin Cooperate to Inhibit
Angiogenic Sprouting and to Promote Vascular
Stabilization
To extend the comparison of phenotypic consequences of
genetic lossofVE-cadherinand lossofS1PR1 toadifferent in vivo
model system, we studied the effects of morpholino-mediated
cdh5 and s1pr1 gene knockdown in zebrafish embryos. Here,
s1pr1 knockdown produced a set of phenotypes reminiscent
of those previously reported for cdh5 morphants (Montero-
Balaguer et al., 2009). Specifically, both knockdown of cdh5
and s1pr1 resulted in reduced blood flow, pericardial, and brain
edema (Figures 6A and S5) and significant vascular hyper-
sprouting in the hindbrain (Figure 6A; Movie S2, C and D). Similar
phenotypes were observed following knockdown of the sphin-
gosine kinase 1 gene (sphk1), partially abrogating endogenous
S1Pproduction, aswell as in silent heart (tnnt2)morphants,which
lack blood flow (Figures 6A and S5; Movie S2, E and F).
Whereas the observed phenotypic similarities between s1pr1
and cdh5 morphants imply that they regulate a common bio-
logical function, they do not indicate if they cooperate molecu-
larly. A way to test if two components operate in a common
pathway is to assess possible synergy through combined inhibi-
tion of the two at levels which, by themselves, have no or minoreffects, but that their combination produced a hypersprouting response compar
quantitative data from different morphants are shown to the right.
(B) Experiments with MS-1 cells sprouting from beads. The presence or abse
pharmacological agents in different concentrations as indicated. All values are m
See also Figure S5.
Developmeneffects (Gore et al., 2008; Pham et al., 2007). Accordingly, we
titrated morpholino concentrations for s1pr1 and cdh5 to
threshold levels where they individually had only minor or no
effects, and than tested them in combination. We found that
combined injection of low dose cdh5 and s1pr1 morpholinos
reproduced the effects of single high dose morpholinos (Figures
6A and S5; Movie S2, G), suggesting that S1PR1 and VE-
cadherin could cooperate molecularly.
We obtained further evidence for a cooperation of S1PR1 and
VE-cadherin through in vitro studies, where MS-1 cells were
allowed to sprout in fibrin gels in the presence or absence of
the VE-cadherin blocking antibody BV13 (Liao et al., 2000).
In this assay,weconfirmed that BV13 treatment enhancedangio-
genic sprouting (Figure 6B), similar to the S1PR1 blocking agent
(R)-W146 (Figure 3D). We next asked if the effects of altered
S1PR1 signaling on VEGF-driven angiogenic sprouting depend
on the VE-cadherin levels. Indeed, we found that the cell scat-
tering effects, caused by S1PR1 inhibition through (R)-W146,
were enhanced in the presence of the VE-cadherin blocking anti-
body. Conversely, the inhibition of sprouting and cell scattering
caused by the S1PR1-specific agonist SEW2871 was counter-
acted by BV13 (Figure 6B). These results demonstrate that the
effects of S1PR1 signaling on VEGF-induced sprouting are
dependent on the level of functional VE-cadherin, suggesting
that S1PR1 and VE-cadherin cooperate to limit sprouting
angiogenesis.
S1PR1 Regulates VEGF-Induced VEGFR2 Signaling
and Subcellular Localization
Our data suggest that VE-cadherin and junctional stability are
critical downstream components in the negative regulation of
angiogenic sprouting exerted by S1PR1. We also show that
VEGF is a driving force for the angiogenic hypersprouting elicited
by S1PR1 inhibition, and that agonists and antagonists of S1PR1
exert strongandopposing effects onVEGF-mediated angiogenic
responses in vitro. Although, in principle, these responses could
be solely caused by changes in endothelial junctional strength
that permit or restrict the release of tip cells for sprouting, they
may also involve altered VEGF receptor signaling. To address
this issue, we studied the effects of pharmacological modulators
of S1PR1 signaling on VEGFR2 signaling in vitro and in vivo.
For the in vitro signaling experiments we used HUVECs pre-
treated with soluble VEGFR1 (sFlt1), which binds to and seques-
ters VEGF, thereby blocking endogenous autocrine/paracrine
VEGF-induced responses. This pretreatment promotes VEGFR2
accumulation at the cell surface and renders the cells sensitive to
synchronous VEGFR2 stimulation by exogenously added VEGF.
Under these conditions, VEGF promoted rapid phosphorylation
of VEGFR2, ERK1/2, and AKT, effects that were efficiently
blocked by S1P (Figure 7A). VEGF further induced relocalization
(Figures 7B and 5C) and degradation (Figure 7A) of VEGFR2,
effects that were also blocked by S1P. These data show that
S1PR1 signaling influences VEGFR2 signaling in vitro.able to the effects of high dose single s1pr1 or cdh5 morpholinos. Normalized
nce of VE-cadherin blocking antibodies (BV13) was combined with S1PR1
ean ± SD. The p value is indicated; Student’s t test.
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Figure 7. S1PR1 Regulates VEGF-Induced
VEGFR2 Signaling and Internalization
(A) VEGF-induced VEGFR2, ERK1/2, and AKT
phosphorylation, and VEGF-induced VEGFR2
degradation in HUVEC cells, are all inhibited
by S1P.
(B) VEGF-induced VEGFR2 internalization is
strongly counteracted by S1P and the S1PR1-
specific agonist SEW2871, but not by the antag-
onist (R)-W146. These effects on VEGFR2 inter-
nalization parallel the effects on junctional
VE-cadherin.
(C) In vivo administration of VEGF and/or S1PR1
pharmacological agents, as indicated, followed
by analysis of VEGFR2, ERK1/2, and AKT phos-
phorylation in lung homogenates. VEGF-induced
VEGFR2 and ERK phosphorylation are both
counteracted by SEW2871, and enhanced by (R)
W-146. Endogenous AKT levels are high but sup-
pressed by SEW2871. IP, immunoprecipitation;
WB, western blotting.
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in vivo, we performed intracardiac administration of VEGF to
animals pretreated systemically with SEW2871 or (R)-W146
and subsequently assessed VEGFR2, ERK1/2, and AKT phos-
phorylation in lung homogenates. Under these conditions,
SEW2871 pretreatment led to a decrease in the VEGF-induced
VEGFR2 phosphorylation, whereas it was increased following
(R)-W146 treatment (Figure 7C). This result is in accordance
with the in vitro signaling and in vitro/vivo angiogenic effects of
the two drugs. (R)-W146 treatment also increased the VEGF-
induced phosphorylation of ERK1/2, whereas the opposite effect
was observed after treatment with SEW2871, in agreement with
the in vitro situation (Figure 7C). AKT phosphorylation in vivo
contrasted to the in vitro situation in that it was endogenously
high and not further increased by VEGF and/or (R)-W146.
However, it was significantly inhibited by SEW2871, in agree-
ment with the in vitro data (Figure 7C).
Combined, these data show that S1PR1-dependent inhibition
of angiogenic sprouting is connected to inhibition of VEGFR2
signaling. These effects of S1P are likely mediated by S1PR1
because the S1PR1-specific agonist SEW2871 mimicked the
S1P-induced effects on VEGFR2, whereas the S1PR1 specific
antagonist (R)-W146 had the opposite effect (Figure 7B). An
additional control for specificity in this regard was provided by
siRNA-mediated S1PR1 knockdown, which enhanced VEGF-
induced VEGFR2 internalization and degradation, and abro-596 Developmental Cell 23, 587–599, September 11, 2012 ª2012 Elsevier Inc.gated the S1P-induced stabilization of
VE-cadherin at cell junctions (Figure 5B).
DISCUSSION
A Revised Concept for Vascular
Stabilization
The recruitment of mural cells and the
deposition of basal membranes are
considered to be crucial steps to
achieve vascular stabilization (reviewed
in Potente et al., 2011). Indeed, it waspreviously proposed that S1PR1 induces vessel stabilization
through mural cell recruitment, particularly around the aorta
(Liu et al., 2000). We confirmed the previously reported aortic
vSMC defect in S1pr1/ embryos, but our observations
suggest that this phenotype occurs secondary to ectopic endo-
thelial hyperplasia and branching at this site. These ectopic
aortic branches connect to a vast glomeruloid network of capil-
laries that penetrates the aortic vSMC coat initially (around
E11.5) at the dorsal side of the aorta and subsequently spreads
ventrally to encircle the vessel before embryonic death at
E13.5–14. Although we noticed regional lack of the vSMC
marker alpha smooth muscle actin (aSMA) in the perforated
aortic wall, in agreement with previous work (Liu et al., 2000),
we found an abundance of NG2 and PDGFRb positive cells in
close association with the hyperplastic endothelial cells, sug-
gesting that S1pr1/ endothelium is capable of recruiting asso-
ciated mural cells also around the aorta. We also found that
vascular extracellular matrix components were abundantly
deposited in S1pr1/ embryos. Our present data thus argue
against defects in mural cell recruitment or vascular matrix
production as mechanism for vascular instability and ectopic
angiogenesis in the absence of S1PR1. The occurrence of
mural cells and matrix deposits around actively sprouting and
remodeling vessels is not unprecedented; rather, it has been
extensively documented both in retinal and tumor angiogenesis
(reviewed in Armulik et al., 2011).
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induces vascular stability directly in endothelial cells. Loss of
S1PR1 leads to exaggerated and ectopic endothelial sprouting
incompatible with embryonic survival. In contrast to other factors
that control angiogenic sprouting (e.g., VEGF/VEGFR2, DLL4/
NOTCH), the onset of the S1PR1 phenotype occurs at a relatively
late developmental stage, well after establishment of the major
vascular networks. Thus, S1PR1 appears to represent a central
component of a biological program that suppresses the angio-
genic responsiveness in vessels at a developmental stage
when vascular stabilization is essential, such as after the onset
of flow and intraluminal pressure. We postulate that blood flow
delivers S1P, which subsequently activates S1PR1 on endothe-
lial cells to restrict their angiogenic responsiveness and to stabi-
lize already established and newly perfused vessels. At the
angiogenic front, this blockade may be inefficient due to
restricted blood flow and low S1pr1 expression.
Mechanism of S1PR1-Induced Vascular Stabilization—
Balancing the Opposing Functions of VE-Cadherin
and VEGFR2
Key insights into themechanism(s) leading to the hypersprouting
phenotype in the S1PR1-inhibited situation were obtained by
studying underlying morphogenetic events. Observations of
endothelial cell sprouting in vitro suggest that S1PR1 signaling
inhibits VEGF-induced sprouting and branching and promotes
the formation of fewer, but consolidated, sprouts. Conversely,
the combination of VEGF stimulation and S1PR1 antagonism
led to an almost complete dissociation of sprouts and extensive
endothelial cell scattering. Time-lapse recordings of sequential
inhibition and activation of S1PR1 further showed that the
scattering phenotype was reversible. Together, these results
demonstrate that S1PR1 activation counteracts VEGF function
and positively regulates endothelial cell adhesion.
A central mediator of endothelial cell adhesion is VE-cadherin,
which becomes strongly increased at endothelial junctions in
response to S1P (Lee et al., 1999). VEGF, on the other hand,
causes junctional VE-cadherin destabilization and triggers its
subsequent internalization (Gavard and Gutkind, 2006). When
costimulating cells with VEGF and S1P, we observed that VE-
cadherin remained stabilized at endothelial junctions and insen-
sitive to the VEGF-induced internalization. This result establishes
a functional antagonism between S1PR1 and VEGFR2 at the
levels of VE-cadherin and junctional stability. Partial inhibition
of VE-cadherin through blocking antibodies showed that the
amount of functional VE-cadherin is critical for S1PR1 to exert
its antiangiogenic effects, demonstrating that VE-cadherin is
a critical downstream mediator of S1PR1 function.
Further evidence for VE-cadherin operating downstream of
S1PR1 comes from the observation that the junctional localiza-
tion of VE-cadherin is disturbed in cultured cells and the mouse
retina as a result of S1PR1 ablation. Furthermore, both in mouse
and zebrafish, S1PR1 ablation causes angiogenic hypersprout-
ing. Our zebrafish data are in agreement with recently published
work, suggesting an inhibitory role for VE-cadherin during angio-
genic sprouting in zebrafish (Montero-Balaguer et al., 2009) and
in vitro (Abraham et al., 2009). In addition, our data show that low
dose morpholinos against S1PR1 and VE-cadherin, which by
themselves had minor effects, resulted in strong phenotypesDevelopmenwhen combined, suggesting that S1PR1 and VE-cadherin oper-
ate in a common pathway.
We also propose a second layer of regulation through which
S1PR1 activity inhibits VEGFR2 signaling. Following S1P stimu-
lation, we observed a decrease in VEGF-induced phosphoryla-
tion of VEGFR2, ERK1/2, and AKT, suggesting that VEGFR2
signaling events are inhibited by S1P. VE-cadherin has also
been reported to antagonize VEGF signaling through recruitment
of phosphatases to the VEGFR2 signaling complex, as well as
through inhibition of VEGFR2 internalization (Lampugnani et al.,
2006; Zanetti et al., 2002). It remains to be clarified if the inhibi-
tory effect of S1P on VEGFR2 signaling is direct, or mediated
through VE-cadherin.
In summary, although further work is required to sort out the
causal relationships between trafficking and signaling of
VEGFR2 downstream of S1PR1 and its relationship to VE-
cadherin stabilization at junctions, our data establish two critical
means by which S1PR1 signaling suppresses endothelial hyper-
sprouting—through stabilization of junctional VE-cadherin and
through inhibition of VEGFR2 phosphorylation and downstream
signaling.
Among the many vascular beds affected by S1pr1 gene dele-
tion, the hyperbranched aorta provides a good illustration of the
critical relevance of S1PR1-dependent stabilization mecha-
nisms in vascular development. The aorta normally displays
a highly stereotyped branching pattern, and deviations would
be expected to have deleterious effects on inner organ anatomy
and function. Whereas angiogenic hypersprouting has been
observed in other genetic mutants, a similarly hyperbranched
aorta has to our knowledge not been described before. Our
observation that ectopic branches initially extend from the dorsal
part of the aortic circumference and in close spatial correlation
with intercostal arteries is noteworthy, given that VEGF
produced by the somites is thought to drive formation of interso-
mitic (prospective intercostal) vessels (Coultas et al., 2005). S1P
distributed via the blood stream may hence work in order to
hinder illegitimate vascular sprouting and branching in major
vessels in response to VEGF.
EXPERIMENTAL PROCEDURES
Detailed protocols and description of reagents used are provided in Supple-
mental Experimental Procedures. The following information is intended for
brief orientation. Animal housing, as well as the experiments performed,
were in accordance with Swedish legislation and were approved by the local
animal ethics committees prior to experimentation.
Mouse Experiments
S1pr1 null and flox alleles and the Cdh5(PAC)-CreERT2 and R26R-EYFP trans-
genic lines have been published previously, whereas the Cdh5 flox allele,
generated by the Dietmar Vestweber Laboratory, is presently unpublished.
For induced gene knockout in embryos and pups, tamoxifen was administered
to the mother and transferred to the offspring via the placenta or the milk. For
pharmacological experiments (R)-W146, SEW2871, VEGF, or vehicle were
administered intraperitoneally (IP) to newborn pups. Histological examinations
of whole-mounted tissues and tissue sections were done using standard tech-
niques essentially as described previously (Gerhardt et al., 2003; Ruhrberg
et al., 2002), using commercially available reagents. For each analysis,
a minimum of three mutants and control littermates were compared. VEGF
signaling in vivo was assessed in lung homogenates after exposure to
SEW2871 or (R)-W146 administered IP, followed by VEGF exposure through
intracardiac injections under full anesthesia.tal Cell 23, 587–599, September 11, 2012 ª2012 Elsevier Inc. 597
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The Tg(fli:eGFP)y1 transgenic line was used. One-to-two cell stage embryos
were injected with morpholino oligonucleotides at different concentrations,
raised at 28C using standard methods, manually dechorionated at 1 dpf
and incubated at 28C before analysis. Prior to scoring or live microscopy,
the morphant embryos were anesthetized. For live imaging of zebrafish hind-
brain development, anesthetized embryos (52–58 hpf) were embedded in low
melting point agarose and analyzed in an upright 2-photon laser scanning
microscope equipped with a 403/1.0 water dipping lens and a Ti:Sapphire
tunable Chameleon Ultra-II infrared laser. For statistical analysis of endothelial
sprouting, embryos were fixed and the hindbrain region was dissected to re-
move surrounding tissues. Filopodia and tip cell numbers were counted in
hindbrains of at least six fish for each group.
Ex Vivo Experiments
Rings (1–2 mm) of the mouse thoracic aorta were embedded between two
disks of collagen type I and cultivated in MCDB131 medium and 10% fetal
calf serum (FCS). Dose-response experiments identified 25 mg/ml for (R)-
W146 and 10 mg/ml for SEW2871 as optimal concentrations for further anal-
ysis, which included the scoring of angiogenic responses and immunohisto-
chemical analysis of vascular cell markers. A minimum of three aortic ring
cultures were analyzed for each condition and experiments were repeated
four times. For each culture, three sampled areas, each of 0.75 mm 3
0.45 mm, at the sprouting front were quantified.
Cell Culture Experiments
Human umbilical vein endothelial cells (HUVECs; passage 5-10) and mouse
pancreatic islet-derived microvascular endothelial cells (MS-1; passage
8-15) were routinely cultured in gelatin-coated tissue culture flasks in EGM-
MV or EGM-II medium, respectively. Normal human skin fibroblasts
(NHSF; passage 2-10) were cultured in DMEM with 5% FCS. For fibrin bead
assays HUVECs or MS-1 cells were mixed with dextran-coated Cytodex 3
microbeads in heparin-containing medium. Cell-coated beads were cultured
over night, re-suspended in fibrinogen, aprotinin and thrombin and allowed
to clot in 24-well tissue culture plates. A feeder layer of NHDFs was seeded
on top of the fibrin gel. Medium was changed regularly with new addition of
drugs (SEW2871, (R)-W146, SU5416), VEGF and/or VE-cadherin blocking
antibody. Bead assays were monitored for 6 days and scored for filopodia,
angiogenic sprouts and dissociated endothelial cells. MS-1 cells stably ex-
pressing a GFP-like protein (copGFP) or mCherry under the CMV promoter
were generated through lentiviral infections and used for time-lapse experi-
ments. For immunofluorescence, MS-1 and HUVEC were growth factor
starved prior to the experiments, then treated with VE-cadherin blocking anti-
body, (R)-W146, S1P, SEW2871, or dynasore hydrochlorate, and finally with
hVEGF165, sFlt1, or SU5416. Cells were stained overnight using VEGFR2
and VE-cadherin antibodies.
Molecular Biology
Real-time quantitative PCR (RTQ-PCR) was performed on RNA from E13.5
S1pr1/ or control embryo microvascular fragments using TaqMan or
Roto-Gene Q commercial reagents and standard protocols. The comparative
CTmethod was used to calculate fold differences. For VE-cadherin and S1PR1
silencing by siRNA, HUVECs, or MS-1 cells were incubated with commercial
reagents according to published protocols. Cells were subsequently stimu-
lated with VEGFR2 and S1PR1 agonists (hVEGF165, SEW2871, S1P) and pro-
cessed for immunohistochemistry.
Biochemistry
As a general approach, growth factor-starved HUVECs and MS-1 cells were
preincubated with S1P or vehicle and processed further according to experi-
ment. For trypsin digestion assays, MS-1 cells were further incubated with
VEGF for 30 min, exposed to trypsin-EDTA, transferred to a protease inhibitor
cocktail and frozen in liquid nitrogen. For VEGF pathway activation, HUVECs
were stimulated with VEGF, rinsed, and frozen. For VEGFR2 inhibition,
HUVECs and MS-1 cells were exposed to SU5416 before stimulation with
VEGF and freezing. For western blot analysis, proteins from frozen cells or
organs were extracted and 10 mg of total proteins separated by SDS-PAGE,
transferred to PVDF membranes and blotted against relevant antibody. For598 Developmental Cell 23, 587–599, September 11, 2012 ª2012 Elsimmunoprecipitation, tissue debris was removed from cell or tissue lysates
by centrifugation and protein concentration determined. Lysates were further
precleared by protein-G-Sepharose, and then exposed to the relevant
antibody precoupled to protein-G-Sepharose beads. Immunocomplexes
were washed and separated by SDS-PAGE, transferred to nitrocellulose
membranes and blotted against relevant antibody. Signals were detected
using horseradish peroxidase-coupled secondary antibodies and commercial
reagents. For multiple probing, membranes were stripped with stripping buffer
and re-probed.
Statistical Analysis
Statistical significancewas determined by using unpaired two-tailed Student’s
t test. Differences were considered significant with a p value <0.05. Quantified
data are presented as mean ± SD.
SUPPLEMENTAL INFORMATION
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